Market Challenges And Opportunities

Peptide Based Infection Therapeutics Market – Drivers

Increase in number of pipeline drugs is expected to drive peptide based infection therapeutics market. For instance, in September 2018, BioAegis Therapeutics Inc. started clinical trials for Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN) in Community-Acquired Pneumonia (CAP), in Australasia and has observed reduced morbidity and mortality in over 20 infectious and non-infectious disease animal models.

Furthermore, LA Jolla Pharmaceutical Company is undergoing phase II clinical trials for LJPC-501, and is expected to complete study in April 2023. This drug can be used for treating Septic Shock.

Peptide Based Infection Therapeutics Market – Restraint

High cost of alternative techniques in manufacturing of peptide drugs to avoid peptide degradation may hamper the growth of the market. For instance, According to an article published in Biomolecule 2017, utilization of techniques such as Liposomes, PEGylation, need to develop for effective peptide drug delivery have increased the overall cost of therapy and thus restraint the growth of the market.